Liquidia (NASDAQ:LQDA) Earns Buy Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Liquidia (NASDAQ:LQDA - Free Report) in a research report report published on Wednesday morning, Benzinga reports. Needham & Company LLC currently has a $28.00 target price on the stock.

LQDA has been the subject of a number of other research reports. HC Wainwright increased their target price on shares of Liquidia from $16.00 to $32.00 and gave the stock a buy rating in a research report on Thursday, March 14th. LADENBURG THALM/SH SH increased their price target on shares of Liquidia from $15.00 to $30.00 and gave the stock a buy rating in a report on Thursday, December 21st. Bank of America increased their price target on shares of Liquidia from $13.00 to $15.00 and gave the stock a buy rating in a report on Thursday, December 21st. Finally, Wedbush reissued an underperform rating and issued a $3.00 price target on shares of Liquidia in a report on Thursday, December 21st. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus price target of $21.00.

Liquidia Price Performance

NASDAQ:LQDA traded down $0.13 on Wednesday, reaching $14.83. 906,886 shares of the company's stock were exchanged, compared to its average volume of 954,361. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -12.36 and a beta of 0.16. Liquidia has a 52 week low of $5.71 and a 52 week high of $16.99. The stock has a fifty day simple moving average of $14.72 and a 200-day simple moving average of $10.68.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its earnings results on Wednesday, March 13th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.19). The business had revenue of $4.53 million for the quarter, compared to the consensus estimate of $5.29 million. Liquidia had a negative return on equity of 132.16% and a negative net margin of 448.89%. As a group, sell-side analysts predict that Liquidia will post -1.01 EPS for the current year.

Insider Activity at Liquidia

In related news, insider Jason Adair sold 4,657 shares of the firm's stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $15.81, for a total value of $73,627.17. Following the sale, the insider now directly owns 108,640 shares of the company's stock, valued at $1,717,598.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Liquidia news, General Counsel Russell Schundler sold 8,653 shares of Liquidia stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $15.82, for a total transaction of $136,890.46. Following the transaction, the general counsel now directly owns 488,087 shares of the company's stock, valued at $7,721,536.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jason Adair sold 4,657 shares of the firm's stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $15.81, for a total transaction of $73,627.17. Following the completion of the transaction, the insider now owns 108,640 shares in the company, valued at approximately $1,717,598.40. The disclosure for this sale can be found here. Insiders have sold 54,605 shares of company stock valued at $862,904 over the last three months. 31.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its holdings in Liquidia by 9.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,342 shares of the company's stock valued at $137,000 after acquiring an additional 989 shares in the last quarter. SkyView Investment Advisors LLC boosted its holdings in Liquidia by 1.4% in the fourth quarter. SkyView Investment Advisors LLC now owns 111,571 shares of the company's stock valued at $1,342,000 after acquiring an additional 1,571 shares in the last quarter. BNP Paribas Arbitrage SNC boosted its holdings in Liquidia by 20.5% in the first quarter. BNP Paribas Arbitrage SNC now owns 9,993 shares of the company's stock valued at $69,000 after acquiring an additional 1,702 shares in the last quarter. Chartwell Investment Partners LLC boosted its holdings in shares of Liquidia by 6.0% during the 4th quarter. Chartwell Investment Partners LLC now owns 31,024 shares of the company's stock valued at $197,000 after buying an additional 1,769 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Liquidia by 7.1% during the 4th quarter. JPMorgan Chase & Co. now owns 27,923 shares of the company's stock valued at $178,000 after buying an additional 1,845 shares in the last quarter. Institutional investors own 64.54% of the company's stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).